临床试验/NCT02678598

NCT02678598已完成不适用

A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Astellas Pharma China, Inc.0 个研究点目标入组 2,555 人开始时间: 2015年3月最近更新: 2016年2月10日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Astellas Pharma China, Inc.
入组人数: 2,555
主要终点: Overall success rate

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

The objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients with invasive fungal infections caused by Candida sp. or Aspergillus sp. (fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients who received Micafungin as empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy
•Patients received Micafungin treatment at least 1 dose

排除标准

•Patients received Micafungin treatment combined with other antifungal drugs at the same time
•Neither efficacy or safety can be evaluated because of missing data, confused record

研究组 & 干预措施

Micafungin group

干预措施: Micafungin (Drug)

结局指标

主要结局

Overall success rate

时间窗: Up to 12 months

Overall success rate=number of overall success patients/number of patients for efficacy evaluation × 100%

次要结局

Overall incidence and severity of adverse events(Up to 12 months)
Overall incidence and severity of adverse drug reactions(Up to 12 months)

研究者

发起方

Astellas Pharma China, Inc.

申办方类型

Industry

责任方

Sponsor

相似试验

终止

4 期

Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive AspergillosisInvasive Aspergillosis

NCT02646774Astellas Pharma China, Inc.43

终止

4 期

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus SppCandidiasisAspergillosis

NCT02646800Astellas Pharma China, Inc.105

终止

3 期

Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICUInvasive Fungal Infections

NCT00048750Astellas Pharma Inc104

已完成

不适用

Study and Analysis of Micafungin for Non-albican Candidemia: Efficacy, Risk Factor and Clinical ManifestationNon-albicans Candidemia

NCT01317394Taipei Medical University WanFang Hospital60

终止

2 期

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for AspergillosisAspergillosis

NCT00047827Astellas Pharma Inc2